Safety, Efficacy of Chadox1 Ncov-19 Vaccine: Rapid Systematic Review and Meta Analysis

Safety, Efficacy and Immunogenicity of Chadox1 Ncov-19 Vaccine: Rapid Systematic Review and Meta Analysis

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05060861

Enrollment

2000

Registered

2021-09-29

Start date

2021-06-01

Completion date

2021-10-30

Last updated

2021-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ChAdOx1 nCoV-19 Vaccine

Keywords

safety, efficacy, immunogenicity, COVID-19 vaccine

Brief summary

Since the beginning of COVID-19 pandemic, a safe and effective vaccine against infection and development of acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed control of the wide spread of COVID-19 and reduce death rates throughout the world. Many clinical trials investigated the immunogenicity of different proposed vaccine including the first distributed vaccine; the ChAdOx1 nCoV-19 vaccine and there is a need to analyze the results of published clinical trials.

Interventions

OTHERChAdOx1 nCoV-19 vaccine

covid-19 vaccine

Study design

Observational model

OTHER

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Inclusion criteria

* Participant who received 2 doses of ChAdOx1 nCoV-19 vaccine

Exclusion criteria

* non vaccinated person

Design outcomes

Primary

Measure	Time frame	Description
To evaluate the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis	up to one year	the frequency of breakthrough COVID-19 infection

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026